Literature DB >> 19898263

Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.

Matthijs L Becker1, Loes E Visser, Ron H N van Schaik, Albert Hofman, André G Uitterlinden, Bruno H Ch Stricker.   

Abstract

OBJECTIVE: Metformin is transported into the hepatocyte by organic cation transporter 1 (OCT1) and out of the hepatocyte by multidrug and toxin extrusion 1 (MATE1). Recently, we discovered that polymorphisms rs622342 A>C in the SLC22A1 gene, coding for OCT1, and rs2289669 G>A in the SLC47A1 gene, coding for MATE1, are associated with the degree of glucose lowering by metformin. In this study, we assessed whether there exists an interaction between these two polymorphisms.
METHODS: We identified all incident metformin users in the Rotterdam Study, a population-based cohort study. Multiplicative interaction between the polymorphisms and change in HbA1c levels was analyzed in 98 incident metformin users.
RESULTS: In incident metformin users with the OCT1 rs622342 AA genotype, genetic variation at the MATE1 rs2289669 polymorphism was not associated with change in HbA1c levels [-0.10; 95% confidence interval (CI): -0.35 to 0.14; P=0.39]. In users with the OCT1 rs622342 AC genotype, there was a tendency between rs2289669 polymorphisms and change in HbA1c (-0.31; 95% CI: -0.65 to 0.03; P=0.070) and in users with the OCT1 rs622342 CC genotype there was a significant association with change in HbA1c levels (-0.68; 95% CI: -1.06 to -0.30; P=0.005). The multiplicative interaction between these two genotypes was statistically significant (-0.52; 95% CI: -0.94 to -0.11; P=0.015).
CONCLUSION: The effect of the MATE1 rs2289669 polymorphism on the glucose lowering effect of metformin is larger in incident users with the OCT1 rs622342 CC genotype than in incident users with the AA genotype. The effect in incident users with the OCT1 rs622342 AC genotype is in between.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19898263     DOI: 10.1097/FPC.0b013e328333bb11

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  50 in total

1.  Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.

Authors:  Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Metformin pathways: pharmacokinetics and pharmacodynamics.

Authors:  Li Gong; Srijib Goswami; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

Review 3.  Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.

Authors:  M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld
Journal:  Pharmacogenomics J       Date:  2016-07-19       Impact factor: 3.550

4.  PharmGKB summary: very important pharmacogene information for SLC22A1.

Authors:  Srijib Goswami; Li Gong; Kathleen Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

5.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

6.  Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers.

Authors:  Mette Marie Hougaard Christensen; Kurt Højlund; Ole Hother-Nielsen; Tore Bjerregaard Stage; Per Damkier; Henning Beck-Nielsen; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

7.  Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.

Authors:  Sung Kweon Cho; Choon Ok Kim; Eun Seok Park; Jae-Yong Chung
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

Review 8.  Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.

Authors:  Piers R Blackett; Dharambir K Sanghera
Journal:  J Clin Lipidol       Date:  2012-04-22       Impact factor: 4.766

9.  Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.

Authors:  Gurusamy Umamaheswaran; Ramakrishnan Geethakumari Praveen; Solai Elango Damodaran; Ashok Kumar Das; Chandrasekaran Adithan
Journal:  Clin Exp Med       Date:  2014-12-10       Impact factor: 3.984

10.  Type 2 Diabetes Genetics: Beyond GWAS.

Authors:  Dharambir K Sanghera; Piers R Blackett
Journal:  J Diabetes Metab       Date:  2012-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.